Nenad Tomasevic, Dren Bio CEO
June 14, 2022 11:15 AM EDT
Financing

Fol­low­ing bis­pe­cif­ic deal with Pfiz­er, qui­et Cal­i­for­nia biotech rais­es $65M, heads to the clin­ic

Lei Lei Wu

News Reporter

At the be­gin­ning of the year, Dren Bio penned a deal with Pfiz­er for a po­ten­tial $1 bil­lion for its bis­pe­cif­ic an­ti­body plat­form. The de­tails …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times